Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-11-12
Disclosure Type: Decision on New Facilities Investment (Amendment Disclosure)
💡 3-Second Summary
Following the final cost settlement of construction, Celltrion has amended its total investment for the new Plant 3 in Songdo, South Korea, down to KRW 256.2B from the previously planned KRW 274B.
📊 1. [Key Disclosure Content & Major Financial Figures Summary]
- Investment Type & Target: New Facility Investment (Construction of Plant 3 at Celltrion Headquarters in Songdo, South Korea)
- Amended Investment Amount (Excluding VAT):
- Before Amendment: KRW 274,000,000,000 (KRW 274B)
- After Amendment: KRW 256,204,000,000 (KRW 256.2B)
- Reason for Amendment: Finalization and correction of the total investment amount following the completion of physical construction cost settlements.
- Ratio to Equity:
- Before Amendment: 9.43%
- After Amendment: 8.81%
- Equity Capital Base: KRW 2,906,958,188,321 (Based on consolidated financial statements as of the end of 2019)
- Investment Period and Timeline:
- Project Period: January 1, 2021 ~ November 30, 2024
- Project Schedule Details:
- Plant 3 Construction: January 2021 ~ November 2023 (35 months)
- Plant 3 Validation: December 2023 ~ November 2024 (12 months)
- Original Board Decision Date: November 18, 2020 (4 outside directors attended, 1 absent)
- Financing & Facility Profile:
- Financing Plan: Retained earnings and long-term borrowings
- Production Capacity Expansion: With the completion of Plant 3 (60,000 liters), total bioreactor production capacity increases from 190,000 liters (Plant 1: 100,000 liters, Plant 2: 90,000 liters) to 250,000 liters in total.
- Note: Since the facility was built on existing land owned by the company, land acquisition costs are excluded from this investment figure.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This filing serves as an administrative regulatory update detailing the finalized capital cost of Celltrion’s Plant 3 construction project, which was originally authorized on November 18, 2020. It reflects the administrative step of reconciling the final expenditures.
From a financial perspective, the final capital allocation was reduced by KRW 17.796B to settle at approximately KRW 256.2B. Consequently, the transaction’s ratio to 2019 equity capital decreased from 9.43% to 8.81%, showing that the actual cash resources used were lower than initially projected. This project was funded through a combination of internal cash reserves and long-term borrowings. Aside from the reduction in capital allocation, the core strategic parameters—specifically the expansion of bioreactor capacity by 60,000 liters to reach a total of 250,000 liters and the scheduled completion date of November 30, 2024—remain identical to the original operational plan.
📝 Editor’s Comment (by K-STOCK Editor)
This fair disclosure registers the post-construction accounting settlement of a massive capital project originally initiated on November 18, 2020. The primary factual correction is the formal book-entry adjustment of final construction outlays to align with actual physical billing data.
Investors should recognize that this reduction does not signal any downscaling or early termination of the operational expansion. It is a mathematical adjustment of completed capital outlays, and the regulatory filing continues to designate the finalized project period ending November 30, 2024, including the designated validation timeline. The fact that a 12-month validation process is integrated into the official schedule remains a specific administrative requirement in the document.
Consequently, the objective checkpoints for investors to monitor going forward are twofold: first, whether the finalized project period ending November 30, 2024, is completed without administrative delays; and second, the subsequent verification of the total bioreactor production capacity being officially updated from 190,000 liters to 250,000 liters (reflecting the 60,000-liter addition) in future periodic operational statements. Tracking these sequential data points remains the necessary pathway to verifying when this capital allocation is successfully concluded.
📢 Disclaimer & Source Information
Source: This content has been structured and newly drafted based on official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).
Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest solely with the investor.
Inquiries: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
